Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $89.93 USD
Change Today +0.76 / 0.85%
Volume 1.7M
MNK On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

mallinckrodt plc (MNK) Snapshot

Open
$88.69
Previous Close
$89.17
Day High
$90.20
Day Low
$87.80
52 Week High
03/23/15 - $134.26
52 Week Low
08/25/15 - $78.57
Market Cap
10.6B
Average Volume 10 Days
2.8M
EPS TTM
$3.83
Shares Outstanding
117.3M
EX-Date
--
P/E TM
23.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for MALLINCKRODT PLC (MNK)

mallinckrodt plc (MNK) Related Businessweek News

View More BusinessWeek News

mallinckrodt plc (MNK) Details

Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provides contrast media and delivery systems comprising ioversol and gadoversetamide injections for diagnostic imaging applications under the Optiray and Optimark brand names with pre-filled syringes and power injectors to the hospitals and imaging centers. It also offers nuclear imaging products consisting of technetium-99m generators under the Ultra-Technekow DTE brand; cold kits; and Octreoscan kits for localization of tumors. The company markets its products to physicians, pharmacists, pharmacy buyers, specialty pharmacies, radiologists, and radiology technicians, as well as distributes its products to drug wholesalers, retail pharmacy chains, hospital networks, ambulatory surgical centers, and governmental agencies; sells and distributes APIs directly or through distributors to other pharmaceutical companies; and markets and distributes nuclear imaging products to radiopharmacies and hospitals. Mallinckrodt Public Limited Company was incorporated in 2013 and is based in Dublin, Ireland.

5,500 Employees
Last Reported Date: 11/25/14
Founded in 2013

mallinckrodt plc (MNK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $905.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $605.1K
Senior Vice President of Global Operations
Total Annual Compensation: $1.4M
Senior Vice President and President of Autoim...
Total Annual Compensation: $400.0K
Chief Strategy Officer and Senior Vice Presid...
Total Annual Compensation: $449.2K
Compensation as of Fiscal Year 2014.

mallinckrodt plc (MNK) Key Developments

Therakos, Inc., Mallinckrodt Public Limited Company - M&A Call

To discuss Mallinckrodt plc's definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc

Mallinckrodt Seeks Acquisitions

Mark Trudeau, President and Chief Executive Officer of Mallinckrodt Public Limited Company (NYSE:MNK) said, "With our new ARD and hospital growth platforms, our opportunity set of strategic, high-value producing acquisition targets has never been better". Mark Trudeau further added, "So, again, our current generics business role is to generate cash for us to drive additional acquisitions and we'll continue to do that".

Mallinckrodt Public Limited Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 27, 2015; Provides Free Cash Flow Guidance for the Full Year of Fiscal 2015

Mallinckrodt Public Limited Company announced unaudited consolidated earnings results for the third quarter and nine months ended June 27, 2015. On a GAAP basis, net income for the third quarter of fiscal 2015 was $58.0 million, or $0.49 per diluted share, compared with a $24.1 million loss, or a $0.41 loss per diluted share, in the prior-year period. After adjusting for certain specified items, diluted non-GAAP adjusted earnings came in at $2.05 per share. For the fiscal 2015 third quarter, Mallinckrodt net sales were $965 million versus $653 million, up 52% on an operational basis compared to the prior year quarter, solid performance primarily reflecting the additions of Acthar and INOmax into its portfolio. Specialty Brands net sales were $446 million, up $361 million, largely due to the inclusion of Acthar. In its Specialty Generics segment, net sales were $308 million, resulting in a decline in operational growth of 5% compared to the prior year. While the company saw continued strength in hydrocodone, resulting from the launch of new Schedule II products earlier in the fiscal year, this was more than offset by a decline in oxycodone as the company anniversary the price resets taken last year, and the continued decline of Methylphenidate ER net sales driven by the FDA's action, last November, changing the rating on its product from AB to BX. For the fiscal 2015 third quarter, adjusted diluted earnings per share were $2.05 compared to $1.20 per share. Operating income was $133.6 million against $13.8 million a year ago. Income from continuing operations was $57.5 million against $6.0 million a year ago. Income from continuing operations was $0.48 per diluted share against $0.42 per diluted share a year ago. For the first nine months of fiscal 2015, net sales were $2.741 billion, compared with $1.751 billion in the first nine months of the prior year, which represents a 56.5% increase. The increase was primarily driven by the inclusion and performance of Acthar, INOMAX and OFIRMEV, and higher net sales in the Specialty Generics segment. On a GAAP basis, net income for the first nine months of fiscal 2015 was $249.5 million, compared with $33.1 million for the same period in fiscal 2014. Diluted earnings per share were $2.11 compared with $0.56 last year. On a non-GAAP basis, adjusted net income was $655.7 million, compared with $179.2 million. Adjusted diluted earnings per share were $5.60, compared with $3.04 last year, an increase of 84.2%. The increase came from all reported segments. Operating income was $356.2 million against $13.0 million a year ago. Income from continuing operations was $226.1 million or $1.91 diluted per share against $33.8 million or $0.56 diluted per share a year ago. Net cash provided by operating activities was $559.2 million against $168.1 million a year ago. Capital expenditures were $92.5 million against $80.1 million a year ago. Acquisitions and intangibles, net of cash acquired was $1,176.3 million against $1,303.2 million a year ago. The company provided free cash flow guidance for the full year of fiscal 2015. The company expects to exit the year with an annualized free cash flow generation run rate of approximately $1 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNK:US $89.93 USD +0.76

MNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $41.03 USD -0.18
Endo International PLC $78.70 USD -0.30
Hospira Inc $89.93 USD +0.01
Lannett Co Inc $49.87 USD -0.17
Pacira Pharmaceuticals Inc/DE $58.83 USD +0.01
View Industry Companies
 

Industry Analysis

MNK

Industry Average

Valuation MNK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MALLINCKRODT PLC, please visit www.mallinckrodt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.